Interleukin 17A: Key Player in the Pathogenesis of Hypertension and a Potential Therapeutic Target-Reference-Cited by-同舟云学术

Interleukin 17A: Key Player in the Pathogenesis of Hypertension and a Potential Therapeutic Target

Published:2021-03 Issue:3 Volume:23 Page:
ISSN:1522-6417
Container-title:Current Hypertension Reports
language:en
Short-container-title:Curr Hypertens Rep

Author:

Davis Gwendolyn K.,Fehrenbach Daniel J.,Madhur Meena S.^ORCID

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11906-021-01128-7.pdf

Reference70 articles.

1. Collaborators GBDRF. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659–724. https://doi.org/10.1016/S0140-6736(16)31679-8.

2. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269–324. https://doi.org/10.1161/HYP.0000000000000066.

3. • Foti K, Wang D, Appel LJ, Selvin E. Hypertension awareness, treatment, and control in US adults: trends in the hypertension control cascade by population subgroup (National Health and Nutrition Examination Survey, 1999-2016). Am J Epidemiol. 2019;188(12):2165–74. https://doi.org/10.1093/aje/kwz177Comprehensive summary of trends in hypertension awareness, treatment, and control increased from 1999-2016, with few changes after 2010. However, disparities in hypertension control are apparent between age, sex, race/ethnicity.

4. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015-2016. NCHS Data Brief. 2017;(289):1–8.

5. Elijovich F, Laffer CL, Sahinoz M, Pitzer A, Ferguson JF, Kirabo A. The gut microbiome, inflammation, and salt-sensitive hypertension. Curr Hypertens Rep. 2020;22(10):79. https://doi.org/10.1007/s11906-020-01091-9.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Psoriasis as a systemic disease;Deutsches Ärzteblatt international;2024-07-12

2. Vascular remodelling in cardiovascular diseases: hypertension, oxidation, and inflammation;Clinical Science;2024-06-26

3. NETosis Drives Blood Pressure Elevation and Vascular Dysfunction in Hypertension;Circulation Research;2024-05-24

4. Inhibition of the mPTP and Lipid Peroxidation Is Additively Protective Against I/R Injury;Circulation Research;2024-05-10

5. Immunoproteasomal Processing of IsoLG-Adducted Proteins Is Essential for Hypertension;Circulation Research;2024-05-10